美亞柏科(300188.SZ)回購註銷16.89萬股限制性股票及完成註銷13.17萬份股票期權
格隆匯11月21日丨美亞柏科(300188.SZ)公佈,此次註銷的股票期權涉及21名激勵對象,註銷的股票期權為13.17萬份,約佔回購註銷前公司總股本8.04億股的0.02%。
此次回購註銷的限制性股票涉及18名激勵對象,回購註銷的限制性股票數量為16.89萬股,約佔回購註銷前公司總股本8.04億股的0.02%,回購總金額136.33萬元。
公司於2019年11月20日在中國證券登記結算有限責任公司深圳分公司完成註銷/回購註銷手續。此次回購註銷完成後,公司總股本由8.0416億股減至8.0399億股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.